UBS has increased its target price for H Lundbeck A/S to DKK 49, while keeping a neutral stance on the stock.

Lundbeck is a pharmaceutical company based in Denmark that specializes in the research, development, manufacturing, and commercialization of drugs for brain diseases such as Alzheimer's, bipolar disorder, depression, epilepsy, Huntington's disease, Parkinson's disease, and schizophrenia.

The company's product portfolio includes medications like Cipralex for depression and anxiety, Ebixa for Alzheimer's disease, Azilect for Parkinson's disease, Xenazine for Huntington's disease, and Sabril for epilepsy.

Lundbeck operates through various subsidiaries, including Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia, and Lundbeck LLC, which strengthens its presence in the global pharmaceutical market.